Abraxis Bioscience, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abraxis Bioscience, Inc.
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
The company’s calcium channel blocker nasal spray rapidly slowed atrial fibrillation patients’ heart rates, showing potential to be an at-home replacement for emergency room-administered treatment.
Four new orphan medicines were among the products recommended for pan-EU marketing approval by the European Medicines Agency this week.
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
- Other Names / Subsidiaries
- Shimoda Biotech Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.